Mon, July 30, 2012
Sun, July 29, 2012
Fri, July 27, 2012
Thu, July 26, 2012
Wed, July 25, 2012
Tue, July 24, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Neogen reports year end results
Mon, July 23, 2012
Sun, July 22, 2012
Sat, July 21, 2012
Fri, July 20, 2012
Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ] - Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012
Wed, July 11, 2012
Tue, July 10, 2012
Mon, July 9, 2012
Fri, July 6, 2012
Thu, July 5, 2012
Wed, July 4, 2012
[ Wed, Jul 04th 2012 ] - Market Wire
Warnex Announces Refinancing
Tue, July 3, 2012
Mon, July 2, 2012

Boston Therapeutics to Present Corporate Update at the SeeThruEquity Microcap Investor Forum


//health-fitness.news-articles.net/content/2012/ .. t-the-seethruequity-microcap-investor-forum.html
Published in Health and Fitness on Monday, July 16th 2012 at 4:21 GMT by Market Wire   Print publication without navigation


July 16, 2012 07:00 ET

Boston Therapeutics to Present Corporate Update at the SeeThruEquity Microcap Investor Forum

MANCHESTER, NH--(Marketwire - Jul 16, 2012) - Boston Therapeutics, Inc. (OTCQB: [ BTHE ])(OTCBB: [ BTHE ]) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that David Platt, Ph.D., Chief Executive Officer, is presenting a corporate update at the SeeThruEquity Microcap Investor Forum at the Cornell Cub in New York City on July 18th, 2012 at 2:00 p.m. 

"With solid progress on two of our products, SUGARDOWN® and PAZ320, we look forward to telling our story to investors," said Dr. Platt. As we expand our corporate and product branding, our goal is to increase awareness about who we are, what we do and the role that our products play in improving people's lives."

Recent Developments

  • The Company recently completed a Phase ll study at Dartmouth Hitchcock Medical Center for PAZ320. Interim trial results indicated no safety concerns from the open label dose escalation crossover trial on Type 2 diabetic patients. 
  • The Company received an equity investment from Advance Pharmaceutical Company (APC). APC is a leading Hong Kong-based pharmaceutical company and currently sells more than 400 types of licensed pharmaceutical products, consisting of prescription and over-the-counter products. APC also made an equity investment in 2011.
  • The Company received its first commercial purchase orders for SUGARDOWN® from Advance Pharmaceutical Company and from a distributor in Italy.
  • Recently, the Company launched SUGARDOWN® in the U.S. at the Endocrinology Annual Meeting in Houston. SUGARDOWN®, a non-systemic chewable tablet to manage blood glucose, is now available at [ www.SUGARDOWN.com ].

About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: [ BTHE ]) is a leader in the field of complex carbohydrates, a specialized field involving understanding the importance of the role that carbohydrates play in biochemistry and progression of diseases. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement designed to moderate post-meal blood glucose; PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN™, an injectable anti-hypoxia drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at [ www.bostonti.com ].

Forward-Looking Statements
The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this press release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.



Publication Contributing Sources